City Therapeutics (CTY) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
City Therapeutics is the larger company by market cap ($1.03 billion vs $983.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTY | OMER |
|---|---|---|
| Share price | $19.32 | $13.21 |
| Market cap | $1.03B | $983.66M |
| 1-day change | +5.29% | -5.71% |
| YTD return | — | -23.11% |
| 1-year return | — | +48.93% |
| 5-year return | — | +77.79% |
| P/E ratio (TTM) | — | 15.92 |
| Forward P/E | — | 11.95 |
| EPS (TTM) | $-2.53 | $0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-3.35M |
| 52-week high | $23.88 | $21.24 |
| 52-week low | $15.81 | $6.70 |
| Distance from 52-week high | -19.10% | -37.81% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +93.22% | +108.18% |
| Average volume | 328.87K | 1.36M |
| Shares outstanding | 53.39M | 74.46M |
| Employees | 75 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About City Therapeutics
CTY stock →City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
CTY vs OMER FAQ
Which is bigger, City Therapeutics or Omeros?
City Therapeutics (CTY) is larger, with a market capitalization of $1.03B compared with $983.66M for Omeros (OMER).
Are City Therapeutics and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.